Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARMOR2: Galeterone in CRPC
NCT01709734Phase 2Terminated
- Sponsor
- LTN Pharmaceuticals, Inc.
- Start
- Dec 2012
- Primary completion
- Sep 2016
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of galeterone in castration-resistant prostate cancer (CRPC), sponsored by LTN Pharmaceuticals, Inc.. Started Dec 2012; status: terminated.
02
Drugs
galeterone
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01709734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01709734.